Theravance Inc  

(Public, NASDAQ:THRX)   Watch this stock  
Find more results for David W. LaMie
26.47
-0.66 (-2.43%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 26.34 - 27.42
52 week 26.04 - 42.96
Open 27.02
Vol / Avg. 682,191.00/1.06M
Mkt cap 2.95B
P/E     -
Div/yield     -
EPS -1.61
Shares 111.52M
Beta 1.29
Inst. own 75%
May 22, 2014
THERAVANCE INC 2014 Annual Shareholder Meeting - 4:00PM EDT - Add to calendar
May 6, 2014
Q1 2014 THERAVANCE INC Earnings Conference Call - 5:00PM EDT - Add to calendar
May 6, 2014
Q1 2014 THERAVANCE INC Earnings Release - 4:00PM EDT - Add to calendar
Apr 9, 2014
THERAVANCE INC at Needham Healthcare Conference
Mar 11, 2014
THERAVANCE INC at Barclays Healthcare Conference
Mar 5, 2014
THERAVANCE INC at Cowen Health Care Conference
Feb 26, 2014
THERAVANCE INC at Citi Global Healthcare Conference
Feb 13, 2014
THERAVANCE INC at Leerink Swann Global Healthcare Conference
Feb 6, 2014
Q4 2013 THERAVANCE INC Earnings Conference Call
Feb 6, 2014
Q4 2013 THERAVANCE INC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -3029.67% -3587.66%
Operating margin -2940.05% -3549.03%
EBITD margin - -3376.63%
Return on average assets -29.73% -32.52%
Return on average equity -63.66% -75.17%
Employees 226 -
CDP Score - -

Address

901 Gateway Boulevard
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-8086000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Its programs include RELVAR or BREO (fluticasone furoate/vilanterol), ANORO (umeclidinium bromide/vilanterol) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc (GSK), and its oral Peripheral Mu Opioid Receptor Antagonist program. Fluticasone Furoate/Vilanterol (FF/VI) is an investigational once-daily inhaled ICS/ LABA combination treatment, comprising fluticasone furoate (FF) and vilanterol (VI), for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) and patients with asthma.

Officers and directors

Rick E. Winningham Chairman of the Board, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Michael W. Aguiar Chief Financial Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Bradford J. Shafer Esq. Senior Vice President, General Counsel, Secretary
Age: 52
Bio & Compensation  - Reuters
Leonard M. Blum Chief Commercial Officer, Senior Vice President
Age: 52
Bio & Compensation  - Reuters
Jeff Jonker Senior Vice President - Corporate and Business Development
Bio & Compensation  - Reuters
Mathai Mammen M.D., Ph.D. Senior Vice President - Research & Early Clinical Development
Age: 45
Bio & Compensation  - Reuters
Frank Pasqualone Senior Vice President - Operations
Age: 57
Bio & Compensation  - Reuters
David L. Brinkley Head - Business Development
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
William H. Waltrip Lead Independent Director
Bio & Compensation  - Reuters
Henrietta Holsman Fore Independent Director
Age: 57
Bio & Compensation  - Reuters